BioCentury
PODCAST | Finance
BioCentury & Getty Images

Finance

Hong Kong rising, plus Varmus’ POV & Biden’s FDA Choice: a BioCentury podcast

The SEHK’s biotech chapter three years on

September 28, 2021 1:32 AM GMT

On the latest BioCentury This Week podcast, BioCentury’s editors discuss how the biotech chapter of the Stock Exchange of Hong Kong has helped the SEHK become the second-largest public market for biotech listings globally, and one that’s poised for more growth. They also discuss takeaways from BioCentury’s conversation with former NIH Director and current Chair of the WHO Science Council Harold Varmus, the choices facing President Joe Biden as he weighs making his pick for permanent FDA commissioner, and this week’s Deal in Focus, a partnership between Incyte Corp. (NASDAQ:INCY) and Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) in graft-versus-host disease.


Purchase Reprint/Distribution Rights
This article may not be distributed to non-subscribers.
Purchase this article for limited one-time distribution and website posting.

Purchase Rights